Catalog No.
Product Name
Application
Product Information
Citations
-
GHRH Antagonist
JV-1-36 is a growth hormone-releasing hormone (GHRH) antagonist. This compound effectively inhibits the production of reactive oxygen species in A549 lung cancer cells, making it a valuable tool for investigating the biological effects of GHRH antagonists. Research applications include in vitro studies focused on cancer biology and role of GHRH in tumorigenesis. -
Growth Hormone-Releasing Factor
GHRF, ovine is a growth hormone-releasing factor that specifically stimulates the secretion of pituitary growth hormone (GH). It plays a crucial role in the physiological response to hypoglycemia, enhancing GH release to regulate metabolic processes. This reagent is utilized in research focused on growth hormone regulation, metabolic disorders, and endocrine system studies. -
Growth Hormone Secretagogue Agonist
L-692429 hydrochloride is a nonpeptidyl growth hormone secretagogue (GHS) agonist and a benzolactam derivative, primarily targeting the growth hormone secretagogue receptor. With a binding affinity characterized by a Ki of 63 nM, this compound effectively stimulates growth hormone release, making it valuable for studies in endocrine regulation and metabolic research. Its applications extend to investigating the physiological roles of growth hormone and exploring therapeutic avenues for growth-related disorders. -
Ghrelin Receptor Agonist
GSK894281 is a highly potent ghrelin receptor agonist exhibiting a pEC50 of <4.9 at the human motilin receptor. This compound demonstrates the ability to penetrate the central nervous system effectively. GSK894281 is primarily utilized in research applications related to gastrointestinal function, particularly for investigating therapies for constipation and facilitating colonic emptying prior to procedures such as colonoscopy or colon surgery. -
GHSR
JMV 3002 is a potent antagonist of the growth hormone secretagogue receptor (GHSR). It exhibits significant biological activity by inhibiting hexarelin-stimulated food intake in rat models, achieving up to 98% reduction at a dose of 80 μg/kg. JMV 3002 does not induce release of growth hormone on its own, nor does it inhibit hexarelin-stimulated growth hormone secretion in infant rats at a dose of 160 μg/kg. This compound is valuable for research focused on energy homeostasis and the regulation of appetite. -
GHSR-1a Agonist
GHSR-1a agonist-1 is a potent agonist of the human growth hormone secretagogue receptor 1a (GHSR-1a), exhibiting an EC50 value of 0.49 nM. This compound effectively stimulates the release of endogenous growth hormone, making it valuable for investigating growth and developmental processes. In preclinical studies, oral administration at a dosage as low as 0.1 mg/kg led to significant increases in body weight and length in 4-week-old rats, supporting its potential applications in addressing growth and development retardation in pediatric research. -
GHS-R1a Antagonist
JMV 3008 is a GHS-R1a antagonist with an IC50 of 5.6 nM, effectively inhibiting the growth hormone secretagogue receptor 1a. This compound demonstrates potential in the study of metabolic disorders, including diabetes and obesity, by modulating appetite and energy homeostasis. Research involving JMV 3008 can contribute valuable insights into therapeutic strategies targeting these diseases. -
GHSR Inverse Agonist
KwFwLL-NH2 is a hexapeptide that functions as an inverse agonist at the growth hormone secretagogue receptor (GHSR). This compound demonstrates moderate potency with an EC50 of 45.6 nM, making it a valuable tool for investigating the role of ghrelin signaling in various biological processes. It is applicable in research focused on appetite regulation, metabolic disorders, and potential therapeutic interventions targeting the ghrelin pathway. -
GLP-1R Agonist
Lotiglipron is an orally active GLP-1 receptor agonist that plays a crucial role in enhancing glucose-dependent insulin secretion and reducing appetite. This compound is primarily utilized in research related to Type 2 diabetes mellitus (T2DM) and metabolic disorders, demonstrating significant effects on glycemic control and weight management. Its unique mechanism makes Lotiglipron a valuable tool for studying potential therapeutic strategies in diabetes treatment. -
Semaglutide Intermediate
tBuO-Ste-Glu(AEEA-AEEA-OH)-OtBu is a key intermediate in the synthesis of Semaglutide, a glucagon-like peptide 1 receptor (GLP-1R) agonist. This compound is essential for facilitating the development of therapeutics targeting GLP-1R, which plays a crucial role in glucose metabolism and appetite regulation. Research applications include the study of metabolic disorders and the development of obesity and diabetes treatments. -
GLP-1R Agonist
Aleniglipron is a potent glucagon-like peptide-1 receptor (GLP-1R) agonist that exhibits an EC50 value of less than 0.1 nM in human-derived beta (HDB) cell lines through cAMP stimulation assays. This compound selectively activates the Gαs-cAMP signaling pathway of GLP-1R, avoiding β-arrestin recruitment. Aleniglipron is demonstrated to enhance insulin release, improve glucose clearance, reduce food intake, and promote weight loss. It serves as a valuable tool in research focused on type 2 diabetes and obesity. -
GLP-1 Analog
GLP-1 (7-36), amide, biotin labeled is a biotinylated analog of human Glucagon-Like Peptide 1, specifically comprising the C-terminal region. This compound serves as a valuable tool for studying GLP-1 receptor interactions and signaling pathways. It is commonly utilized in research applications focused on metabolic disorders, diabetes, and obesity, providing insights into peptide hormone functions and their implications in therapeutic development. -
GPCR Agonist
Tryptophan-cholic acid (Trp-CA) serves as an agonist for the orphan G protein-coupled receptor MRGPRE, exhibiting an EC50 of 9.6 μM. This compound facilitates the secretion of glucagon-like peptide GLP-1, improving glucose tolerance in diabetic mouse models. Although Trp-CA is orally effective, its poor absorption and inability to cross the blood-brain barrier limit its systemic application. Its primary research applications focus on understanding mechanisms in type 2 diabetes (T2D) and investigating treatments for insulin secretion and hepatic steatosis associated with high-fat diets. -
GLP-1R PAM
V-0219 is an orally active positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R). This compound enhances GLP-1R signaling, making it a valuable tool for studying therapeutic strategies in obesity-associated diabetes and related metabolic disorders. Its mechanism of action offers potential insights into the modulation of glucose homeostasis and appetite regulation. -
GLP-1R Modulator
LSN3160440 is an allosteric modulator of the GLP-1 receptor (GLP-1R) that enhances protein-protein interactions, effectively functioning as a molecular glue. By stabilizing the binding of inactive GLP-1 (9-36) NH2 to GLP-1R, it facilitates receptor activation and downstream signaling. This compound is valuable in studying metabolic disorders and diabetes-related research, providing insights into GLP-1R modulation and its therapeutic potential. -
Antioxidant Agent
Cinnamtannin A2, a tetrameric procyanidin, functions as a potent antioxidant agent. It has been shown to enhance GLP-1 levels and stimulate insulin secretion in murine models. Additionally, Cinnamtannin A2 upregulates the expression of corticotropin-releasing hormone and demonstrates significant anti-diabetic and nephroprotective effects, making it valuable for research in metabolic and renal health. -
GLP-1 Receptor Agonist
Albiglutide fragment is a GLP-1 receptor agonist that corresponds to a biologically active form of the GLP-1 (7-36) analog. This peptide plays a crucial role in modulating glucose metabolism by stimulating insulin secretion and reducing glycosylated hemoglobin (A1C) levels, making it a valuable tool in type 2 diabetes (T2D) research. Its unique structure, derived from a DPP-4 resistant GLP-1 dimer fused with the human albumin gene, enhances its stability and provides insights into long-acting therapeutic options for diabetes management. -
GLP-1 Receptor Agonist
(4S)-GLP-1 receptor agonist 14 is a potent agonist targeting the GLP-1 receptor, exhibiting an EC50 of ≤ 20 nM. This compound is effective in stimulating insulin secretion and has applications in the study of diabetes, obesity, and metabolic disorders. Additionally, it may provide insights into cardiovascular diseases, liver diseases, and nonalcoholic steatohepatitis (NASH), making it a valuable tool for researchers investigating GLP-1 receptor-related pathways. -
GLP-1 Agonist
GLP-1R agonist 10 is a potent GLP-1 receptor agonist, exhibiting an EC50 of 0.051 nM. This compound stimulates insulin secretion in a glucose-dependent manner, thereby enhancing glucose homeostasis. It is primarily utilized in research applications focused on metabolic disorders, diabetes treatment, and the mechanistic study of GLP-1 signaling pathways. -
GLP-1 Agonist
GLP-1 receptor agonist 7 is a highly effective agonist targeting the glucagon-like peptide-1 (GLP-1) receptor. This compound stimulates cAMP production via GLP-1R activation with an EC50 of ≤ 0.2 nM. GLP-1 receptor agonist 7 is valuable for research applications related to metabolic disorders, particularly type 2 diabetes, facilitating the investigation of GLP-1-mediated pathways and potential therapeutic interventions. -
GLP-1 Receptor Agonist
GLP-1 receptor agonist 11 is a selective agonist of the glucagon-like peptide-1 (GLP-1) receptor. This compound demonstrates significant biological activity in stimulating insulin secretion and inhibiting glucagon release, making it a valuable tool in diabetes research. Additionally, GLP-1 receptor agonist 11 may be applied in studies related to non-alcoholic fatty liver disease, offering insights into metabolic regulation and potential therapeutic strategies. -
GLP-1 Antagonist
Exendin(9-39) amide acetate is a potent glucagon-like peptide-1 (GLP-1) antagonist that selectively competes with endogenous GLP-1 for the GLP-1 receptor (GLP-1R). By inhibiting GLP-1 signaling, it counteracts the physiological effects associated with elevated GLP-1 levels. This reagent is particularly valuable for research into postbariatric hypoglycemia (PBH) and other metabolic disorders where GLP-1 modulation is critical. -
GLP-1 Activator
3-Deoxyglucosone is a GLP-1 activator that plays a critical role in the Maillard reaction and the polyol pathway. This reactive intermediate interacts with protein amino groups to produce advanced glycation end products (AGEs), particularly imidazolone, the most specific AGE for 3-Deoxyglucosone. Additionally, it enhances GLP-1 secretion in the presence of low glucose levels, positioning it as a valuable biomarker for diabetes research. -
GLP Receptor Agonist
GLP-1 receptor agonist 14 is a potent agonist of the glucagon-like peptide-1 (GLP-1) receptor. This compound demonstrates significant biological activity in promoting insulin secretion and enhancing glucose-dependent insulin release, making it a valuable tool for research in diabetes and metabolic disorders. Its unique properties facilitate investigations into GLP-1 signaling pathways and therapeutic strategies for metabolic diseases. -
GLP-1R PAM
V-0219 hydrochloride is a positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). This compound has demonstrated oral bioactivity and is pertinent in the study of obesity-associated diabetes. Its ability to enhance GLP-1R signaling makes it a valuable tool for research into metabolic disorders and therapeutic interventions targeting glucose homeostasis. -
GLP1R Agonist
DD202-114 is a selective agonist of the glucagon-like peptide-1 receptor (GLP1R), demonstrating significant potential for therapeutic applications in type 2 diabetes mellitus and obesity. This compound promotes cAMP accumulation, which is crucial for insulin secretion and glucose homeostasis. DD202-114 also exhibits inhibition of the hERG channel with an IC50 of 15.9 μM and demonstrates strong CYP2C8 inhibition with an IC50 of 0.22 μM. Additionally, it effectively reduces blood glucose levels and food intake, making it a valuable tool for research in metabolic disorders. -
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist 10 is a potent agonist of the glucagon-like peptide-1 (GLP-1) receptor. It has demonstrated the ability to inhibit food intake and reduce glucose excursions in mice, making it a valuable tool for investigating metabolic disorders. This compound is particularly relevant for research applications focused on type 2 diabetes (T2DM) and obesity, providing insights into potential therapeutic strategies for these conditions. -
GLP-1R Agonist Isomer
(1R)-GLP-1 receptor agonist 12 is an isomer targeting the GLP-1 receptor (GLP-1R). It exhibits significant agonistic activity, which can stimulate insulin secretion and enhance β-cell function. This compound is particularly relevant in diabetes research and the study of metabolic disorders, making it a valuable tool for exploring therapeutic strategies in glucose homeostasis and appetite regulation. -
GLP-1R Agonist
GLP-1R agonist 12 is a selective agonist for glucagon-like peptide-1 receptors (GLP-1R), which are integral to glucose metabolism and insulin secretion. This compound promotes insulin release and inhibits glucagon secretion, making it a valuable tool in diabetes research. Its activity may aid in the exploration of therapeutic strategies for metabolic disorders and related conditions. -
GLP Receptor Agonist
Bofanglutide is an analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist, exhibiting an EC50 of 0.677 nM. This compound demonstrates significant efficacy in ameliorating type 2 diabetes by enhancing insulin secretion, suppressing glucagon release, and promoting β-cell proliferation. Bofanglutide is a valuable tool for diabetes research and therapeutic development targeting metabolic disorders. -
GLP-1 Receptor Agonist
GLP-1 receptor agonist 12 is a potent agonist targeting the glucagon-like peptide-1 (GLP-1) receptor. This compound enhances insulin secretion and exhibits glucose-dependent effects, making it instrumental in diabetes research. Its mechanism of action provides valuable insights into the regulation of glucose homeostasis and potential therapeutic strategies for metabolic disorders. -
Liraglutide Side Chain
Pal-Glu(OSu)-OH is a side chain of Liraglutide, which functions as a glucagon-like peptide-1 (GLP-1) receptor agonist. This compound is pivotal in research relating to type 2 diabetes mellitus, facilitating the study of metabolic regulation and therapeutic strategies targeting GLP-1 pathways. Its utilization aids in advancing knowledge in diabetes treatment and obesity research. -
GLP-1R Inhibitor
GLP-1 receptor agonist 13 is a selective agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 76 nM. This compound plays a significant role in enhancing glucose-dependent insulin secretion, thereby influencing metabolic processes. It is particularly useful in research applications focused on diabetes, obesity, and related metabolic disorders. -
GLP Inhibitor
MS012 is a selective glucagon-like peptide (GLP) inhibitor with an IC50 value of 7 nM. This compound serves as a valuable tool in the investigation of GLP dysregulation associated with various conditions, including cancer, inflammatory diseases, and neuroregenerative disorders. Its application in research may facilitate the understanding of GLP's role in these pathophysiological processes. -
GLP-1 Antagonist
Imapextide is a glucagon-like peptide-1 (GLP-1) receptor antagonist that plays a critical role in the study of hypoglycemia. By inhibiting GLP-1 activity, Imapextide provides insights into glucose homeostasis and insulin secretion regulation. It is a valuable tool for researchers investigating metabolic disorders and the physiological effects of GLP-1 signaling. -
GLP-2R Agonist
Sonefpeglutide is a potent glucagon-like peptide-2 (GLP-2) receptor agonist, exhibiting an EC50 value of 0.327 nM for human GLP-2R. This long-acting analog is designed without a PEG linker and is fused to a human IgG Fc fragment, resulting in an extended half-life in vivo. Sonefpeglutide is particularly relevant for research into short bowel syndrome and related gastrointestinal disorders. -
GLP-1 Analog
HAEGTFTSDVSSYLE is a GLP-1 analog designed to interact with GLP-1 receptors, mimicking the activity of endogenous glucagon-like peptide-1. This polypeptide exhibits key biological activities including the stimulation of insulin secretion and the inhibition of glucagon release, thereby regulating glucose homeostasis. HAEGTFTSDVSSYLE is utilized in research applications related to diabetes treatment, metabolic disorders, and obesity studies. -
Anti-GLP-1 receptor Antibody
Efmedaglutide alfa is an anti-GLP-1 receptor antibody designed to interact specifically with the glucagon-like peptide-1 receptor. This fusion protein exhibits potent biological activity, promoting insulin secretion and inhibiting glucagon release, making it a useful tool in studies related to diabetes and metabolic disorders. Its application in research can aid in understanding the role of GLP-1 signaling in glucose homeostasis and potential therapeutic interventions for related diseases. -
Anti-GLP-1 receptor Antibody
Efsubaglutide alfa is an anti-GLP-1 receptor antibody designed to target and inhibit the GLP-1 receptor, a key regulator of glucose metabolism and insulin secretion. This fusion protein exhibits potent biological activity in modulating glucose homeostasis and is primarily utilized in diabetes research. Its application extends to studies focused on the therapeutic potential for metabolic disorders and obesity management. -
GIPR/GLP-1R Agonist
Zantrutide is an agonist of the glucagon, gastric inhibitory polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). It exhibits significant biological activity in the modulation of glucose metabolism and insulin secretion. This compound is valuable for research applications targeting metabolic diseases, particularly in the exploration of obesity and type 2 diabetes treatment strategies. -
GLP-1R PAM
(S)-V-0219 is a selective positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). It induces calcium flux in HEK293 cells expressing human GLP-1R, enhancing receptor activity. In vivo studies demonstrate that (S)-V-0219 is orally bioavailable, effectively reducing hyperglycemia in murine models while also suppressing feeding behavior in fasting conditions. This compound presents valuable applications in diabetes research and appetite regulation studies. -
GLP-1R Agonist
GLP-1R Agonist 18 is a potent agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 of 0.044 nM. This compound enhances insulin secretion in response to glucose, making it a valuable tool for research in diabetes and metabolic disorders. Its high affinity for GLP-1R positions it as a significant candidate for investigating therapeutic strategies targeting glucose homeostasis and appetite regulation. -
GLP-1 Analogue
Vurolenatide is a long-acting GLP-1 analogue that targets the glucagon-like peptide-1 receptor. It exhibits significant biological activity by enhancing insulin secretion, promoting satiety, and reducing gastric emptying, making it relevant for metabolic studies. Vurolenatide is particularly useful in research applications focusing on short bowel syndrome and disorders related to glucose metabolism. -
GLP-1R Agonist
GLP-1R agonist 15 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound plays a significant role in enhancing insulin secretion, inhibiting glucagon release, and promoting glucose-dependent insulin action. It is primarily utilized in research focused on metabolic disorders, including diabetes and obesity, and may aid in the development of novel therapeutic strategies targeting GLP-1R pathways. -
GLP Receptor Agonist
GLP-1R agonist 21 is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting a potent binding affinity with an EC50 of 0.0104 nM. This compound enhances insulin secretion, promotes glucose-dependent insulin release, and plays a critical role in glucose homeostasis. It is primarily utilized in research related to metabolic disorders, diabetes, and obesity, providing valuable insights into therapeutic strategies targeting GLP-1R pathways. -
GLP-1R Agonist
Linvixdutide is a potent GLP-1 receptor (GLP-1R) agonist known for its anti-obesity effects. By stimulating the GLP-1 pathway, it promotes insulin secretion, reduces glucagon release, and enhances satiety, making it a valuable tool in obesity research. This compound may also have applications in the study of metabolic disorders and diabetes management. -
GLP Receptor Agonist
GLP-1 receptor agonist 15 selectively targets the GLP-1 receptor with an EC50 of 0.74 nM, demonstrating potent activity. This compound has an IC50 value of 10.1 μM for the hERG potassium ion channel, indicating a suitable safety profile. GLP-1 receptor agonist 15 is primarily utilized in diabetes research, providing valuable insights into glucose metabolism and insulin signaling pathways. -
GLP-1R Agonist
GLP-1R agonist 19 is a potent and selective agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound demonstrates excellent plasma stability and liver microsomal stability, making it suitable for in vitro and in vivo studies. Additionally, it exhibits low hERG toxicity, ensuring a reduced risk of off-target effects. Research applications include investigations into glucose homeostasis, metabolic disorders, and potential therapeutics for type 2 diabetes. -
GLP Receptor Agonist
GLP-1R agonist 20 (Compound I-132) is a selective agonist for the glucagon-like peptide-1 receptor (GLP-1R), exhibiting an EC50 value of 0.0162 nM. This compound plays a crucial role in enhancing insulin secretion and promoting glucose homeostasis. It is valuable for research applications focused on metabolic disorders such as type 2 diabetes and obesity. -
GIPR Antagonist
GIPR Antagonist 2 is a potent antagonist of the GIP receptor, which plays a crucial role in glucose metabolism and energy homeostasis. This compound demonstrates significant potential for research applications related to obesity and type 2 diabetes. Its ability to inhibit GIPR signaling provides a valuable tool for investigating the underlying mechanisms of metabolic disorders and evaluating therapeutic strategies.
